You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back


Go to Close Top

Augmentin is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. 12The beta-lactamase inhibitory action of clavulanate extends the spectrum of amoxicillin to embrace a wider range of organisms, including many resistant to other beta-lactam antibiotics. 12

Augmentin is indicated for the short-term treatment of infections caused by susceptible bacteria, including:* 1-5

Augmentin is indicated for the treatment of the following infections in adults and children:

  • Acute bacterial sinusitis (adequately diagnosed) 1-5
  • Acute otitis media 2-5
  • Acute exacerbations of chronic bronchitis (adequately diagnosed) 2-5
  • Community acquired pneumonia 2-5
  • Cystitis 1-5
  • Pyelonephritis 1-5
  • Cellulitis 1-5
  • Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis 1-5
  • Bone and joint infections, in particular osteomyelitis 2-5

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Using Augmentin

Augmentin is available in many different forms, including: 1-5

Augmentin should be used in accordance with local official antibioticprescribing guidelines and local susceptibility data. 1-5

For more information on dosing and administering Augmentin, visit


  1. Augmentin 250 mg/125 mg film-coated tablets SPC available on last accessed July 2017
  2. Augmentin 500mg/125mg Film-coated Tablets SPC available on last accessed July 2017
  3. Augmentin DUO Suspension 400/57mg SPC available on last accessed May 2019
  4. Augmentin 875/125mg Film Coated tablets SPC available on last accessed July 2017
  5. Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension SPC available on last accessed July 2017

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Augmentin is a registered trademark of the GlaxoSmithKline group of companies